Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Patients must sign and date an Informed Consent consistent with International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) guidelines and local regulation prior to participation in the trial.~2. Patients must agree to cooperate with all trial evaluations and perform all required tasks.~3. Patients with acute gastric or intestinal spasm-like pain (without severe vomiting and surgical acute abdomen).~4. Male or female patients aged 18 to 70 years.~5. The pain intensity upon screening is at least point 6 on a 0-10 numerical rating scale (NRS).~Exclusion criteria:~1. Patients with the following concomitant disease is not eligible for enrollment:~   * Painful gastric or intestinal spasm of organic origin such as Crohn's disease, ulcerative colitis, lactose intolerance, gastrointestinal perforation, suspected gastrointestinal perforation or peritoneal effusion.~  * Pain related with malignancy.~  * Patients with other severe pain states of organic origin.~  * Mechanical stenosis of the gastrointestinal tract ,megacolin.~  * Urinary retention associated with mechanical stenosis of urinary tract.~  * Narrow-angled glaucoma.~  * Tachyarrhythmia.~  * Myasthenia gravis.~  * Meulengracht-Gilbert syndrome.~  * Known depression or known mental illness, anxiety disturbance.~2. Patients taking the following concomitant medication within 7 half-life of concomitant medication (the duration from taking concomitant medication to attending the trial is less than 7 half-life) are not eligible for enrollment:~   * Analgesics,~  * Spasmolytics,~  * Anticholinergics~  * Affecting gastrointestinal motility, such as propantheline, metoclopramide, cisapride, loperamide, diphenoxylate, opioid analgesics, antacids and other ulcer treatment~  * Regular administration of laxatives~  * Narcotics~  * Antidepressant treatment or treatment with psychoactive drugs~3. Pregnancy and/or lactation or planned pregnancy;~4. Known hypersensitivity to N-butylscopolammonium bromide~5. Alcohol, or drug abuse.~6. Simultaneous participating in another clinical trial, or discontinuing from another clinical trial before randomization (administration of study medication); moreover, in the case of screening failure or premature discontinuing from the trial, repeated enrollment is forbidden.~7. Unwilling to or unable to complete the entire trial procedure according to the protocol.~8. In investigator's opinion, the patient is not proper for the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Buscopan® (hyoscine butylbromide) (Type: EXPERIMENTAL): 1st injection of Buscopan® solution 20mg, if necessary 2nd injection after 20min of the 1st injection
- 654-II(anisodamine) (Type: ACTIVE_COMPARATOR): 1st injection of 654-II solution 10mg, if necessary 2nd injection after 20min of the 1st injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete